Wikidata entity: Q64222877
Quantities
| P4135 | maximum age | 75 |
| P2899 | minimum age | 19 |
| P1132 | number of participants | 283 |
| P6099 | clinical trial phase | ... | Q42824827 (phase III clinical trial) | phase III clinical trial |
| P582 | end time | ... | 2016-02-01 | ??? |
| P31 | instance of | ... | Q30612 (clinical trial) | clinical trial |
| P1050 | medical condition | ... | Q147778 (liver cirrhosis) | liver cirrhosis |
| P1050 | medical condition | ... | Q1546498 (metabolic dysfunction–associated steatotic liver disease) | metabolic dysfunction–associated steatotic liver disease |
| P6153 | research site | ... | Q39997 (Korea University) | Korea University |
| P6153 | research site | ... | Q4403855 (Seoul National University Hospital) | Seoul National University Hospital |
| P580 | start time | ... | 2014-02-01 | ??? |
| P8363 | study type | ... | Q78089383 (interventional study) | interventional study |
| P1476 | title | Monolingualtext | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis | ??? |
| P3098 | ClinicalTrials.gov ID | NCT02068339 |
Why not click here or view trends?
log id: 5111535